BSEBoard Meeting2d ago · 12 Aug 2026, 03:23 pm
Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting ....
Indo Us Bio-Tech Ltd · 541304
✦ AI SummaryResults
Indo Us Bio-Tech Ltd has announced the outcome of its board meeting held on August 12, 2026, where the board approved unaudited financial results for the quarter ended June 30, 2026, along with limited review reports from the auditor.
Analysis Scores
Earnings Impact6/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk4/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Indo Us Bio-Tech Ltd - 541304 - Board Meeting Outcome for Outcome Of Board Meeting Held On August 12, 2026, Pursuant To Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
Attachments (1)
📄pdf
Download →
7d15bfd1-0654-4738-b537-3d7128636baf.pdf
View document text
& INDO US A"
BIO-TECH LIMITED
Indo-US (AN ISO CERTIFIED COMPANY)
Agiiieeds CIN LO1122GJ2004PLC043550
Date: 12 August, 2026
BSE Limited National Stock Exchange of India Limited
Dept. of Corporate Services, Dept. of Corporate Compliances,
Phiroze Jeejeebhoy Towers, Exchange Plaza, C-1 Block-G,
Dalal Street, Bandra Kurla Complex,
Mumbai- 400 001 Bandra (E) Mumbai- 400 051
BSE Scrip Code - 541304 NSE Symbol: INDOUS
Sub: Outcome of Board Meeting held on August 12, 2026, pursuant to Regulation 30 of the
SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015.
Dear Sir,
Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements)
Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting
held on Wednesday, 12 August, 2026 at the registered office of the Company situated at 309, Shanti
Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have
considered and approved the following items of business:
1. The Board approved unaudited financial results of the company for the quarter ended 30 June,
2026 along with limited review reports obtained from the Auditor of the Company.
The Board Meeting commenced at 14.30 P.M. and concluded at 15:10 P.M.
You are requested to kindly take the same on record.
Thanking you,
For, Indo us Bio Tech Limited
DIMPY Digeallysanebdy DIVPY
DIVANGERALIOSH.
DIVYANGBHAI pate. 2026081 151357
JOSHI o530’
Ms. Dimpy Joshi
Company Secretary & Compliance officer
| DSIR RECOGNITION IN HOUSE RAD UNIT
E-mail : indous_jagdish{@yanoo.cion + indo-us_agrisciencesg@hotrm
Wob " www indousaiseods com
7i INDO US §
BIO-TECH LIMITED
Indo-US (AN 1SO CERTIFIED COMPANY)
Agriseeds CIN LO1122GJ2004PLC043550 o
T Us Blotech e
oo ans e, Satachar CO hI aN r: HL a0 s1 t1 a2 O2 pG pJ .2 0 N0 a4 wP a( n C go T4 o3 w5 e5 r0 , Sola Road, Abmedabad, Gularat 380081
B¢ o |Particusars Statement of Standalone Unau Bdite d Financial Resuits for
ut ah re iq eu ra r Et ne dr
nded on_June 30, 2026
1 [Refvrome Opnerautioens June 30, 2026 March 31,2026 June 30, 2025 March 31,2026
2 | TO ot th ae lr I i nn cc oom me e 33 ,, 32 10 1 18 2 .. . 06 3 58 8 22 ,6 600 422 .14 65 27 33 ,, 00 77 706 ... 119 156
11,043 91
3 P|uErxcpehnassees :o-f stock in trade
Production Expenses 52419 30837 71514 311691
[( PC rh oga rn eg sse i asn n n d Sv toe ckn it n To rof a r dF ei .in ieshsed Goods, Workin. 862.55 344093 88395 783404 ;
[FEimnpalnocyee Geo Bsetnse fits Expense } 1,2 23e1 65 2. 899 946 (1,9 2460 3 67 0.. 915 3 798 6) ! 8 4 21 35 03 2, .. ,1 002 0 464 (2. 1292 5464 02. 38 212 3 23)| {| |
54 |[ EP xr co ef pi tt i( oL no as ls )
tb ee mf so .r e
r‘ ie ox rc e Pp et ri io on da l
ti et me sm s and tax 3, 302 006 738 ..6 3. 759 0°0 2, 233 369 r64 .. 85 8 26 0 2, 452 808 165 ... 915 929 9 11 , ,, 6 31 5 97 7 23 .
3 06 1 20
|P |r To afi xt
a xf pt ee nr
ee xceptional item before tax
307.70 237.82 481.99
1,392.-
D Te of te alr re Td ax T Ea xx p
eCnh
E aax crp gse
n ses! (Written back) ©3a .2 7r 57s
02 1135 8.81 7523
Ti46 .89 705
s N2a
8 |NetProfit/(Lfoors tsh)ep eriod/year
9 [Other comprehensive income (net of tax) 303.74 19797 47024 1,312.29
tBA o..
(((( ri1ii
o)) )
Il iI tt tnn
ac mm
nsos
dm tt
e hh
a oT att sa
ww sx ii
el n lbn d
ao t ta
ib eb
gv oar a se
sc til efa mis ses di
f hti aoe
wt ioo
r bto eaf .rni et
o fs is
00 .. 00 2)8 ] { 00. .2 09 7)] 0 0. .7 28 0)]
10 |Total Comprehensive Income
- 0.06 ©21) ©.B
11 | |P sa hi ad r- e)u p equity share capital (face value of Rs.10 per 303.74 187.11 47045 1,312.87
|O -DEt BiPh alSe
i t (y
a( cex ec Vl au ldi un eg
r fe Rv sa .l 1u 0a /t -i eon ar ce hs )e
rve)
2,005.20 2,005.20 2,005.20 2 7, .0 20 45 8. .2 10
~Adjusted
11.5511 00.5988 223355
66.5544
Notes *not annualised 1.51 0.98 235 6.54
|t (1 h) e T Ch oe m f pi an nan yc i ha al v r ee s eu xl pt rs ew se sr ee d r ae nv ui ne mw oe dd i b fiy e t dh ‘e o pA iu nd ii ot n C oo nm tm hi et st ee re e sa uln td s. a pproved by the Board of Directors at its meeting held on 12.08.2026 and the Statutory Auditors
(g 4{ ) T;) hv e7h f%‘ ic gwo uem rrp esea n hny ao i v s i e nd b ve eea s el t ni on r rg eci o gn m rpo oln uae pi‘ n etm sa j nor p eP nr do jd ngu , uc It r es ce ag im ve men dt , d ui. re. i nS g ‘e te hd e pCu el rt i mi ov gat ui no dn e, r P y ar ro pc ie es ws .i ng & Trading.
CMARTERED ACCOUNTANTS
For and on behalf of Boargl of Dire tors |
Vi h D Ajudiya)
Piac Managing Director|
DIN: 01745951|
Regd, Office: VXSSTTHSH Y DSIRRECOGNSNIITTIOIN ON IN HOUSE R&D UNIT
, Shanti Mall, Sattadhar Cross Road, Factory A ddre€ ss : s
gopgp N:Vlflng Tower, Ahmedabad-380 061. x‘::rg:::i?amfigg.?r"%:-bengam'
L"é&i"?‘ifié&ffiifiéw" Dist-Gandhinagar, Gujarat,
E-mail : indousexim@gmail.com e Web : www.indousagriseeds.com
BHAGAT & ASSOCIATES
CHARTERED ACCOUNTANTS
oB-1204, SHIoLP CORPORATE P T
CAR. K. BHAGAT BODAKDEV, AHMEDABAD-380054
CA MANISH BHAGAT @({ Q) +9197252 57136, +91 98790 61500
= bhagatasso@gmail.com,
CA SHIKHA BHAGAT
CA SUNIL PATEL | N D I A rkmbhagat@gmail.com
@ https:;//www.bhagatandassociates.org
CA VAIBHAV SHINGALA
INDEPENDENT AUDITOR'S REVIEW REPORT ON THE
QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND-
AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO
REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND
DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED.
LIMITED REVIEW REPORT
The Board of Directors,
Indo US Bio-Tech Limited,
Ahmedabad, Gujarat
1. We have reviewed the accompanying standalone statement of unaudited financial
results of Indo US Bio-Tech Limited (CIN: L01122GJ2004PLC043550) (the
company) for the quarter ended 30th June 2026 ('The Statement') being submitted
by the Company pursuant to the requirements of regulation 33 of the Securities
and Exchange Board of India (Listing Obligation and Disclosure Requirements)
Regulation 2015 as amended (Listing Regulations).
2. This standalone statement which is the responsibility of the Company's
Management and has been approved by the Board of Directors, has been
prepared in accordance with Ind-AS 34 -Interim Financial Reporting'
prescribed under section 133 of the Companies Act. 2013 (the Act) read with
relevant rules issued there under and other recognized accounting practices and
policies generally accepted in India. Our responsibility is to issue a report on these
standalone financial statements based on our review. 0
3. We conducted our review of the standalone Statement in accordance with the
Standard on Review Engagements (SRE) 2410 "Review of Interim Financial
Information Performed by the Independent Auditor of the Entity", issued by the
Institute of Chartered Accountants of India. This standard requires that we plan
and perform the review to obtain moderate assurance as to whether the
standalone financial statements are free of material misstatement. A review of
interim financial information consists of making inquiries, primarily of persons
responsible for financial and accounting matters, and applying analytical and
other review procedures. A review is substantially less in scope than an audit
conducted in accordance with Standards on Auditing and consequently does not
enable us to obtain assurance that we would become aware of all significant
matters that might be identified in an audit. Accordingly, we do not express an
audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that
causes us to believe that the accompanying standalone statement of unaudited
financial results prepared in accordance with applicable accounting standards
specified under Section 133 of the Companies Act, 2013 as amended, read with
relevant rules made thereunder and other accounting principles generally
accepted in India and other recognized accounting practices and policies has not
disclosed the information required to be disclosed in terms of Regulation 33 of the
SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
including the manner in which it is to be disclos
[Showing first 8,000 characters — download PDF for full document]